Compare NINE & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NINE | PMN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Pharmaceuticals and Biotechnology |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5M | 23.5M |
| IPO Year | 2018 | N/A |
| Metric | NINE | PMN |
|---|---|---|
| Price | $0.49 | $7.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $72.67 |
| AVG Volume (30 Days) | ★ 1.0M | 41.7K |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $571,171,000.00 | N/A |
| Revenue This Year | $4.56 | N/A |
| Revenue Next Year | $1.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.59 | N/A |
| 52 Week Low | $0.37 | $6.27 |
| 52 Week High | $1.78 | $39.75 |
| Indicator | NINE | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 50.39 | 96.32 |
| Support Level | $0.42 | $0.29 |
| Resistance Level | $0.49 | $7.95 |
| Average True Range (ATR) | 0.04 | 0.39 |
| MACD | 0.01 | 0.80 |
| Stochastic Oscillator | 83.29 | 97.13 |
Nine Energy Service Inc is a North American onshore completion and production services provider. It targets unconventional oil and gas resource development. It operates in one segment, Completion Solutions. The Completion Solutions segment offers cementing services; completion tools, including liner hangers and accessories, frac sleeves, fully composite frac plugs, and specialty open hole float equipment and centralizers and other services. It operates in the U.S, Canada, and other countries where majority of the revenue is generated from the United States.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.